Cargando…
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401484/ https://www.ncbi.nlm.nih.gov/pubmed/34625408 http://dx.doi.org/10.1158/1078-0432.CCR-21-2404 |
_version_ | 1784772977551736832 |
---|---|
author | Henriksen, Tenna Vesterman Tarazona, Noelia Frydendahl, Amanda Reinert, Thomas Gimeno-Valiente, Francisco Carbonell-Asins, Juan Antonio Sharma, Shruti Renner, Derrick Hafez, Dina Roda, Desamparados Huerta, Marisol Roselló, Susana Madsen, Anders Husted Løve, Uffe S. Andersen, Per Vadgaard Thorlacius-Ussing, Ole Iversen, Lene Hjerrild Gotschalck, Kåre Andersson Sethi, Himanshu Aleshin, Alexey Cervantes, Andres Andersen, Claus Lindbjerg |
author_facet | Henriksen, Tenna Vesterman Tarazona, Noelia Frydendahl, Amanda Reinert, Thomas Gimeno-Valiente, Francisco Carbonell-Asins, Juan Antonio Sharma, Shruti Renner, Derrick Hafez, Dina Roda, Desamparados Huerta, Marisol Roselló, Susana Madsen, Anders Husted Løve, Uffe S. Andersen, Per Vadgaard Thorlacius-Ussing, Ole Iversen, Lene Hjerrild Gotschalck, Kåre Andersson Sethi, Himanshu Aleshin, Alexey Cervantes, Andres Andersen, Claus Lindbjerg |
author_sort | Henriksen, Tenna Vesterman |
collection | PubMed |
description | PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. EXPERIMENTAL DESIGN: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. RESULTS: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. CONCLUSIONS: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438 |
format | Online Article Text |
id | pubmed-9401484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-94014842023-01-05 Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences Henriksen, Tenna Vesterman Tarazona, Noelia Frydendahl, Amanda Reinert, Thomas Gimeno-Valiente, Francisco Carbonell-Asins, Juan Antonio Sharma, Shruti Renner, Derrick Hafez, Dina Roda, Desamparados Huerta, Marisol Roselló, Susana Madsen, Anders Husted Løve, Uffe S. Andersen, Per Vadgaard Thorlacius-Ussing, Ole Iversen, Lene Hjerrild Gotschalck, Kåre Andersson Sethi, Himanshu Aleshin, Alexey Cervantes, Andres Andersen, Claus Lindbjerg Clin Cancer Res Precision Medicine and Imaging PURPOSE: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early relapse detection may have a major impact on treatment decisions and patient management for stage III colorectal cancer patients. Beyond assessing the predictive power of postoperative ctDNA detection, we explored the added benefits of serial analysis: assessing adjuvant chemotherapy (ACT) efficacy, early relapse detection, and ctDNA growth rates. EXPERIMENTAL DESIGN: We recruited 168 patients with stage III colorectal cancer treated with curative intent at Danish and Spanish hospitals between 2014 and 2019. To quantify ctDNA in plasma samples (n = 1,204), 16 patient-specific somatic single-nucleotide variants were profiled using multiplex-PCR, next-generation sequencing. RESULTS: Detection of ctDNA was a strong recurrence predictor postoperatively [HR = 7.0; 95% confidence interval (CI), 3.7–13.5; P < 0.001] and directly after ACT (HR = 50.76; 95% CI, 15.4–167; P < 0.001). The recurrence rate of postoperative ctDNA-positive patients treated with ACT was 80% (16/20). Only patients who cleared ctDNA permanently during ACT did not relapse. Serial ctDNA assessment after the end of treatment was similarly predictive of recurrence (HR = 50.80; 95% CI, 14.9–172; P < 0.001), and revealed two distinct rates of exponential ctDNA growth, slow (25% ctDNA-increase/month) and fast (143% ctDNA-increase/month; P < 0.001). The ctDNA growth rate was prognostic of survival (HR = 2.7; 95% CI, 1.1–6.7; P = 0.039). Serial ctDNA analysis every 3 months detected recurrence with a median lead-time of 9.8 months compared with standard-of-care computed tomography. CONCLUSIONS: Serial postoperative ctDNA analysis has a strong prognostic value and enables tumor growth rate assessment. The novel combination of ctDNA detection and growth rate assessment provides unique opportunities for guiding decision-making. See related commentary by Morris and George, p. 438 American Association for Cancer Research 2022-02-01 2021-10-08 /pmc/articles/PMC9401484/ /pubmed/34625408 http://dx.doi.org/10.1158/1078-0432.CCR-21-2404 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Precision Medicine and Imaging Henriksen, Tenna Vesterman Tarazona, Noelia Frydendahl, Amanda Reinert, Thomas Gimeno-Valiente, Francisco Carbonell-Asins, Juan Antonio Sharma, Shruti Renner, Derrick Hafez, Dina Roda, Desamparados Huerta, Marisol Roselló, Susana Madsen, Anders Husted Løve, Uffe S. Andersen, Per Vadgaard Thorlacius-Ussing, Ole Iversen, Lene Hjerrild Gotschalck, Kåre Andersson Sethi, Himanshu Aleshin, Alexey Cervantes, Andres Andersen, Claus Lindbjerg Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title | Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title_full | Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title_fullStr | Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title_full_unstemmed | Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title_short | Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences |
title_sort | circulating tumor dna in stage iii colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences |
topic | Precision Medicine and Imaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401484/ https://www.ncbi.nlm.nih.gov/pubmed/34625408 http://dx.doi.org/10.1158/1078-0432.CCR-21-2404 |
work_keys_str_mv | AT henriksentennavesterman circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT tarazonanoelia circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT frydendahlamanda circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT reinertthomas circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT gimenovalientefrancisco circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT carbonellasinsjuanantonio circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT sharmashruti circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT rennerderrick circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT hafezdina circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT rodadesamparados circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT huertamarisol circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT rosellosusana circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT madsenandershusted circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT løveuffes circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT andersenpervadgaard circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT thorlaciusussingole circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT iversenlenehjerrild circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT gotschalckkareandersson circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT sethihimanshu circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT aleshinalexey circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT cervantesandres circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences AT andersenclauslindbjerg circulatingtumordnainstageiiicolorectalcancerbeyondminimalresidualdiseasedetectiontowardassessmentofadjuvanttherapyefficacyandclinicalbehaviorofrecurrences |